SEARCH

SEARCH BY CITATION

References

  • 1
    The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 2
    Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 1997; 15: 357365.
  • 3
    Zakko SF, Seifert HA, Gross JB. A comparison of midazolam and diazepam for conscious sedation during colonoscopy in a prospective double-blind study. Gastrointest Endosc 1999; 49: 684689.
  • 4
    Waring JP, Baron TH, Hirota WK et al. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. Gastrointest Endosc 2003; 58: 317322.
  • 5
    Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy, Lichtenstein DR, Jagannath S, Baron TH et al. Sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2008; 68: 815826.
  • 6
    Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999; 66: 3339.
  • 7
    Gan TJ. Pharmacokinetic and pharmacodynamic characteristics of medications used for moderate sedation. Clin Pharmacokinet 2006; 45: 855869.
  • 8
    Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 4157.
  • 9
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. DHHS 2008; 1139.
  • 10
    Hughes SC. HIV and anesthesia. Anesthesiol Clin North America 2004; 22: 379404.
  • 11
    de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42: 223282.
  • 12
    Piscitelli SC, Kress DR, Bertz RJ, Pau A, Davey R. The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy 2000; 20: 549553.
  • 13
    Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999; 91: 681685.
  • 14
    Chhajed PN, Wallner J, Stolz D, Baty F, Strobel W, Brutsche MH, Tamm M. Sedative drug requirements during flexible bronchoscopy. Respiration 2005; 72: 617621.
  • 15
    Rosario CM, Kadiev S, Nagaraja H, Diaz PT. Evaluating the safety of midazolam for procedural sedation in human immunodeficiency virus-seropositive patients on protease inhibitors. ACCP Chest Conference Presentation. October, 2007.
  • 16
    Gastaldo JM, Neidig JL, Para MF, Diaz PT, Koletar SL. The clinical significance of the drug interaction between protease inhibitors and midazolam. Abstr Intersci Conf Antimicrob Agents Chemother 2000; 40: 13.
  • 17
    Hsu AJ, Carson KA, Yung R, Pham PA. Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy. Pharmacotherapy 2012; 32: 538545.